A long-standing scar on the abdomen of healthy woman

Mohammed Shanshal1, Nihull Jakharia-shah2

1Consultant dermatologist, Basildon University Hospital, UK, 2ST3 Speciality Trainee, Basildon University Hospital, UK

Corresponding author: Mohammed Shanshal, MBChB, EBDV, FABMS, E-mail: mohammed.shanshal@nhs.net

A 42-year-old woman presented with scar-like hyperpigmentation on the lower right abdominal quadrant. The lesion had been asymptomatic and had been present since early childhood following a varicella infection at the age of six. The patient initially believed the lesion to be a chickenpox scar and was reassured by her GP. The patient’s medical history included depression and fibromyalgia.

On examination, a scar-like atrophic hyperpigmented patch was detected (Figs. 1a and 1b). Dermoscopy showed a brownish, structureless background with no pigment network (Fig. 1c). On palpation, a 3 x 1.5 cm deeply seated nodule was detected. A fast-tracked ultrasound was ordered and revealed a well-defined hyperechoic solid lesion with no vascularity (Fig. 2). Due to clinical suspicion, a deep incisional biopsy was performed (Fig. 3a – 3c).

QUESTION 1: WHAT IS THE MOST LIKELY DIAGNOSIS?

A. Cellular dermatofibroma
B. Piloleiomyoma
C. Dermatofibrosarcoma protubersans
D. Nodular fasciitis
E. Plexiform neurofibroma

A- Cellular Dermatofibroma - Incorrect

A histologic variant of dermatofibroma, which shares the same clinical features as classical dermatofibroma. It presents as a firm papule, plaque, or nodule. Histologically, it is characterized by highly cellular with a dense aggregation of fibrohistiocytic cells distributed among coarse collagen bundles with a tendency for subcutaneous extension. As opposed to diffuse staining in DFSP, CD34 is usually positive at the periphery of the lesion [1].

B- Piloleiomyoma - Incorrect

Piloleiomyoma is a soft tissue tumor that arises from smooth muscles. It presents as a solitary or multiple firms and usually painful papules or nodules. It can develop sporadically or as part of Reed syndrome [2]. Histologically, it is characterized by interweaving bundles of smooth cells admixed with collagen bundles.

C- Dermatofibrosarcoma Protubersans - Correct

DFSP is a rare and locally aggressive soft tissue cutaneous sarcoma. Typically, DFSP presents as a asymptomatic, slowly enlarging indurated plaque or, less commonly, as a firm cutaneous nodule on the trunk and proximal extremities. Histologically, it shows spindle cells arranged in a storiform pattern.

D- Nodular Fasciitis - Incorrect

Pseudosarcomatous neoplasm presents as a rapidly growing subcutaneous nodule. Histologically, it is characterized by a highly cellular circumscribed mass composed of spindle cells in fibromyxoid stroma situated deeply in subcutaneous tissue, fascia, and/or muscles with increased mitotic activity [3].

E- Plexiform Neurofibroma - Incorrect

It occurs as a part of neurofibromatosis type 1 and presents as small, soft plaques or nodules which may
cell bundles with wavy nuclei in myxoid and collagen stroma [4].

**QUESTION 2: WHAT IS THE MOST COMMON GENETIC ABNORMALITY ASSOCIATED WITH THIS LESION**

A. MYH9-USP6
B. COL1A1-PDGFB
C. FIP1L1–PDGFRA
D. TMPRSS2:ERG
E. BCR-ABL

**A- MYH9-USP6- Incorrect**

This fusion gene is present in most of the nodular fasciitis cases.

**B- COL1A1-PDGFB- Correct**

DFSP shows a characteristic translocation between chromosomes 17 and 22 known as t (17; 22) (q22; q13), leading to the formation of COL1A1-PDGFB fusion genes. This results in an increase in the expression of PDGFB, which is the key factor in tumorigenesis in most of DFSP cases. This translocation can be used as a diagnostic tool in cases with atypical morphology.

**C- FIP1L1–PDGFRA- Incorrect**

This fusion protein is found in some cases of hypereosinophilic syndrome.

**D- TMPRSS2:ERG- Incorrect**

This fusion gene is associated with prostate cancer.

**E- BCR-ABL- Incorrect**

This fusion gene is associated with chronic myeloid leukemia.

**QUESTION 3: WHICH MOLECULARLY TARGETED THERAPY IS USED FOR ADVANCED CASES OF THIS LESION**

A. Vismodegib
B. Cemiplimab
C. Vorinostat

have palpable cords of thickened nerve fibers (bag of worms). Histologically, it is composed of spindle cell bundles with wavy nuclei in myxoid and collagen stroma [4].
D. Ipilimumab  
E. Imatinib

**A- Vismodegib- Incorrect**
Vismodegib is used for advanced basal cell carcinoma.

**B- Cemiplimab- Incorrect**
Cemiplimab is used in advanced cutaneous squamous cell carcinoma.

**C- Vorinostat- Incorrect**
Vorinostat is used to treat cutaneous T-cell lymphoma.

**D- Ipilimumab- Incorrect**
Ipilimumab is used for malignant melanoma.

**E- Imatinib- Correct**
Imatinib, a tyrosine kinase inhibitor, has been reported as a useful option for advanced unresectable, metastatic, and/or recurrent DFSP [5].

**REFERENCES**